Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT03864185||Recruiting||The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies||
||Other / Industry||
||25||All||12 Years and older (Child, Adult, Older Adult)||NCT03864185||CAMCR-011
|RECIPE||March 28, 2019||September 30, 2021||September 30, 2021||March 6, 2019||March 29, 2019||